We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Mylan’s Diabetes Drug’s Lower Price Will Benefit Payers, Not Patients
Mylan’s Diabetes Drug’s Lower Price Will Benefit Payers, Not Patients
Generics company Mylan along with Biocon Biologics launched their diabetes drug Semglee, a version of Lantus, this week, touting it as 65 percent less expensive than other long-acting insulin products on the market.